Cargando…
Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials
Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930786/ https://www.ncbi.nlm.nih.gov/pubmed/33718791 http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.009 |
_version_ | 1783660156460990464 |
---|---|
author | Nada, Khaled M. Nishi, Shawn |
author_facet | Nada, Khaled M. Nishi, Shawn |
author_sort | Nada, Khaled M. |
collection | PubMed |
description | Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems. |
format | Online Article Text |
id | pubmed-7930786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-79307862021-03-12 Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials Nada, Khaled M. Nishi, Shawn Mayo Clin Proc Innov Qual Outcomes Review Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems. Elsevier 2020-12-11 /pmc/articles/PMC7930786/ /pubmed/33718791 http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.009 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Nada, Khaled M. Nishi, Shawn Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials |
title | Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials |
title_full | Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials |
title_fullStr | Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials |
title_full_unstemmed | Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials |
title_short | Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials |
title_sort | endoscopic lung volume reduction: review of the emprove and liberate trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930786/ https://www.ncbi.nlm.nih.gov/pubmed/33718791 http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.009 |
work_keys_str_mv | AT nadakhaledm endoscopiclungvolumereductionreviewoftheemproveandliberatetrials AT nishishawn endoscopiclungvolumereductionreviewoftheemproveandliberatetrials |